false
0001380106
0001380106
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2026
Rapid Micro Biosystems, Inc.
(Exact name of Registrant as Specified in Its
Charter)
| Delaware |
001-40592 |
20-8121647 |
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
25 Hartwell Avenue,
Lexington, MA |
|
02421 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
| |
|
|
Registrant’s Telephone Number,
Including Area Code: (978) 349-3200
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading
symbol(s) |
|
Name
of each exchange
on which registered |
| Class A common stock, $0.01 par value per share |
|
RPID |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 1.01. |
Entry into a Material Definitive Agreement. |
On November 16, 2026, Rapid Micro Biosystems, Inc.,
a Delaware corporation (the “Company”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners
(“Parent”), and EMD Holdings NewCo II, Inc, a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”),
entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the
terms and subject to the conditions therein, Purchaser will commence a cash tender offer (the “Offer”) to acquire all
of the issued and outstanding shares of Class A common stock, $0.01 par value per share, and Class B common stock, $0.01 par
value per share (collectively “Company Common Stock”), at a price per share of $0.75 (the “Offer Price”),
without interest and subject to any withholding of taxes required by applicable law. The Offer will initially expire at one minute after
11:59 p.m. Eastern Time on the date that is 10 business days following the commencement of the Offer, subject to extension under
certain circumstances.
Purchaser’s obligation to accept for payment
shares of Company Common Stock validly tendered pursuant to the Offer is subject to the satisfaction or waiver, to the extent permitted
under applicable legal requirements, of certain conditions set forth in the Merger Agreement, including that (i) there shall have been
validly tendered (and not validly withdrawn) shares of Class A common stock (“Class A Common Shares”) that, considered
together with all other Class A Common Shares (if any) owned by Parent and its affiliates, but excluding Class A Common Shares that have
not yet been “received” (as such term is defined by Section 251(h)(6) of the DGCL), would represent one more Class A Common
Share than 50% of the total number of (1) Class A Common Shares issued and outstanding as of immediately following the “consummation”
of the Offer (as such term is defined in Section 251(h)(6) of the DGCL) plus (2) any Pre-Funded Warrant Shares (as defined below) (the
“Minimum Condition”); (ii) the representations and warranties of the Company contained in the Merger Agreement shall
be accurate, subject to customary materiality thresholds and exceptions; (iii) the Company shall have complied with and performed in all
material respects each of the covenants and other obligations contained in the Merger Agreement; (iv) since the execution and delivery
of the Merger Agreement, there shall not have occurred any Material Adverse Effect (as defined in the Merger Agreement) that is continuing
as of the expiration of the Offer; (v) there shall not have been issued by any governmental body of competent jurisdiction and remain
in effect any order, nor shall any law have been promulgated, enacted, issued or deemed applicable to the Offer or the Merger by any governmental
body that remains in effect, in each case that prohibits or makes illegal the consummation of the Offer or the Merger; and (vi) other
customary conditions set forth in Annex I of the Merger Agreement.
Following the consummation of the Offer, upon
the terms and subject to the conditions set forth in the Merger Agreement, and in accordance with the DGCL, Purchaser will merge with
and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the “Merger”).
The Merger will be governed by Section 251(h) of the DGCL, with no stockholder vote required in order to consummate the Merger.
Pursuant to the Merger Agreement, at the effective
time of the Merger (the “Effective Time”), by virtue of the Merger and without any action on the part of any stockholder
of the Company, each share of Company Common Stock (other than shares of Company Common Stock (a) held by the Company (or held in the
Company’s treasury), Parent, Purchaser or any of their direct or indirect wholly owned subsidiaries, (b) irrevocably accepted for
purchase in the Offer, or (c) with respect to which the holders thereof have properly exercised and perfected demands for appraisal in
accordance with Section 262 of the DGCL) will be converted into the right to receive the Offer Price, in cash, without interest and subject
to any withholding of taxes required by applicable law (the “Merger Consideration”).
In addition, at the Effective Time, by virtue
of the Merger and without any action on the part of any holder thereof:
| · | each
option to purchase shares of Company Common Stock (each, a “Company Option”) (or portion thereof) that is vested and outstanding
as of immediately prior to the Effective Time (taking into account any acceleration of vesting that occurs as of immediately prior to
the Effective Time pursuant to the terms of such Company Option as in effect on the date of the Merger Agreement) will automatically
be cancelled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholding, equal
to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such vested
Company Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the per
share exercise price of such Company Option;
|
| · | each Company Option that is unvested and outstanding
as of immediately prior to the Effective Time (taking into account any acceleration of vesting that occurs as of immediately prior to
the Effective Time pursuant to the terms of such Company Option as in effect on the date of the Merger Agreement) will be converted into
a fixed cash-based award (a “Parent Cash-Based Option Award”) representing the right to receive an amount in cash,
without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the
total number of shares of Company Common Stock subject to such unvested Company Option immediately prior to the Effective Time multiplied
by (ii) the excess, if any, of the Merger Consideration over the per share exercise price of such Company Option. Each Parent Cash-Based
Option Award will continue to vest on the same vesting schedule, and will otherwise remain subject to the same terms and conditions (subject
to certain exceptions), as applied to the corresponding Company Option (or portion thereof) immediately prior to the Effective Time; |
| · | each Company Option, whether vested or unvested,
with a per share exercise price equal to or greater than the Merger Consideration will be cancelled for no consideration; |
| · | each restricted stock unit award in respect of
shares of Company Common Stock that is subject only to time-based vesting (each, a “Company RSU”) that is vested and outstanding
as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms of such Company RSU
as in effect on the date of the Merger Agreement) will be cancelled and converted into the right to receive an amount in cash, without
interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total
number of shares of Company Common Stock subject to such vested Company RSU awards immediately prior to the Effective Time multiplied
by (ii) the Merger Consideration; |
| · | each Company RSU award (or portion thereof) that
is unvested and outstanding immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms
of such Company RSU as in effect on the date of the Merger Agreement) will be converted into a fixed time-based cash-based award (a “Parent
Cash-Based RSU Award”) representing the right to receive an amount in cash, less any applicable tax withholding, equal to
the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such unvested
Company RSU award immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. Each Parent Cash-Based RSU
Award will continue to vest on the same vesting schedule, and will otherwise remain subject to the same terms and conditions (subject
to certain exceptions), as applied to the corresponding Company RSU immediately prior to the Effective Time; |
| · | each restricted stock unit award in respect of
shares of Company Common Stock that is subject to both time-based and performance-based vesting (each, a “Company PSU”)
that is vested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant
to the terms of such Company PSU as in effect on the date of the Merger Agreement) will be cancelled and converted into the right to receive
an amount in cash, without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent)
of (i) the number of shares of Company Common Stock subject to such vested Company PSU award immediately prior to the Effective Time
multiplied by (ii) the Merger Consideration; provided that, for purposes of determining the number of Company PSUs outstanding immediately
prior to the Effective Time, with respect to any portion of the Company PSU award with a performance period that has not been completed
as of such time, any applicable performance-based conditions shall be deemed to have been achieved at target performance; and |
| · | each Company PSU award (or portion thereof)
that is unvested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant
to the terms of such Company PSU as in effect on the date of the Merger Agreement) will be converted into a fixed performance-based cash-based
award (a “Parent Cash-Based PSU Award”) representing the right to receive an amount in cash, less any applicable tax
withholding, equal to the product (rounded down to the nearest whole cent) of (i) the number of shares of Company Common Stock subject
to such unvested Company PSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration; provided that, for purposes
of determining the number of Company PSUs outstanding immediately prior to the Effective Time, with respect to any portion of the Company
PSU award with a performance period that has not been completed as of such time, any applicable performance-based conditions shall be
deemed to have been achieved at target performance. Each Parent Cash-Based PSU Award will continue to vest on the same performance-based
vesting schedule, and will otherwise remain subject to the same terms and conditions (subject to certain exceptions), as applied to the
corresponding Company PSU immediately prior to the Effective Time.
|
Pursuant to the Merger Agreement, with respect
to the Company’s 2021 Employee Share Purchase Plan (the “ESPP”), the Company will take all actions necessary
so that (i) no new participants may join the ESPP and current participants may not increase their payroll deductions or purchase
elections, (ii) no new offering period will begin under the ESPP after the date of the Merger Agreement, and (iii) if the purchase
date for the current offering period would otherwise fall on or after the Effective Time, that offering period will end on a new final
purchase date no later than five business days before the Effective Time. The ESPP will terminate effective immediately prior to, and
subject to, the consummation of the Merger.
Further, at the Effective Time (except as otherwise
noted below):
| · | each warrant to purchase Class A Common Shares issued by the Company on each of May 20, 2026 and May 29,
2026, with an initial exercise price of $1.955 per Class A Common Share (the “Series A Common Stock Warrants”) that
is issued and outstanding shall, in accordance with its terms, become exercisable by the holder thereof solely for an amount in cash equal
to (i) the Merger Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately
prior to the Effective Time, the holder of the number of shares then issuable upon exercise in full of such Series A Common Stock Warrant,
without regard to any limitations on exercise contained therein, less (ii) the exercise price per share of such Series A Common Stock
Warrant, in each case without interest, and less any applicable Tax withholding; |
| · | each warrant to purchase Class A Common Shares issued by the Company on each of May 20, 2026 and May 29,
2026, with an initial exercise price of $2.34 per Class A Common Share (the “Series B Common Stock Warrants”) that
is issued and outstanding shall, unless otherwise elected by the holder thereof in accordance with its terms, and in accordance with the
Series B Warrant Cancellation Agreements (as defined in the Merger Agreement), be cancelled and purchased by Parent, such that Parent
will pay to each holder of a Series B Common Stock Warrant an amount in cash equal to the Black Scholes Value (as defined in the Series
B Common Stock Warrants) of the remaining unexercised portion of such Series B Common Stock Warrant; |
| · | each warrant to purchase Class A Common
Shares issued on August 8, 2025, with an initial exercise price of $3.35 per Class A Common Share (the “2025 Warrants”)
that is issued and outstanding shall, in accordance with the 2025 Warrant Cancellation Agreements (as defined in the Merger Agreement),
as applicable, be terminated and cancelled without any consideration; |
| · | each pre-funded warrant to purchase Class A
Common Shares issued by the Company on May 20, 2026, with an initial exercise price of $0.01 per Class A Common Share (the “Pre-Funded
Warrants”) that is issued and outstanding shall, in accordance with its terms, be deemed to be exercised in full by the holder
thereof in a “cashless exercise” pursuant to the terms thereof effective immediately prior to and contingent upon the occurrence
of the Effective Time, it being understood that any shares issued upon such deemed “cashless exercise” (such shares, the “Pre-Funded
Warrant Shares”) shall be treated pursuant to Section 2.5 of the Merger Agreement and no separate consideration
shall be payable to the holder of any such Pre-Funded Warrant; |
| · | each warrant to purchase shares of Company preferred stock designated as series A1, with an initial exercise
price of $0.01 per share, which were converted into warrants to purchase Class A Common Shares with an exercise price of $0.05 per share
on July 14, 2021 (the “Converted Series A-1 Preferred Stock Warrants”) and each warrant to purchase shares of Company
preferred stock designated as series B1, with an initial exercise price of $0.01 per share, which were converted into warrants to purchase
Class A Common Shares with an exercise price of $0.05 per share on July 14, 2021 (the “Converted Series B-1 Preferred Stock Warrants”)
shall, at the time of the acceptance of the Company Common Stock in the Offer, be terminated in exchange for an amount in cash equal to
(i) the Merger Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately
prior to the Effective Time, the holder of the number of shares then issuable upon exercise in full of such Converted Series A-1 Preferred
Stock Warrant and Converted Series B-1 Preferred Stock Warrant, as applicable, without regard to any limitations on exercise contained
therein, less (ii) the exercise price per share of such Converted Series A-1 Preferred Stock Warrant and Converted Series B-1 Preferred
Stock Warrant, as applicable, in each case without interest, and less any applicable tax withholding; |
| · | each warrant to purchase shares of Company preferred
stock designated as series C1, with an initial exercise price of $1.15 per share, which were converted into warrants to purchase Class A
Common Shares with an exercise price of $5.75 per share on July 14, 2021 (the “Converted Series C-1 Preferred Stock
Warrants”) shall be terminated in exchange for the right of the holder to receive an amount in cash equal to (i) the Merger
Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately prior to the
Effective Time, the holder of the number of shares then issuable upon exercise in full of such Converted Series C-1 Preferred Stock
Warrant, without regard to any limitations on exercise contained therein, less (ii) the exercise price per share of such Converted
Series C-1 Preferred Stock Warrant, in each case without interest, and less any applicable tax withholding; and |
| · | each warrant to purchase Class A Common
Shares issued on April 12, 2018, with an initial exercise price of $1.00 per Class A Common Share (the “2018 Warrants”)
shall be automatically terminated and cancelled pursuant to the terms thereof without any consideration. |
The Merger Agreement includes customary representations,
warranties and covenants of the Company, Parent and Purchaser for a transaction of this nature, including covenants regarding the operation
of the Company’s business prior to the Effective Time.
The Company has agreed to customary “no-shop”
restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations
with third parties regarding acquisition proposals. Notwithstanding these restrictions, the Company may under certain circumstances provide
information to and participate in discussions or negotiations with third parties with respect to an unsolicited bona fide written
Acquisition Proposal (as such term is defined in the Merger Agreement) that the board of directors of the Company (the “Company
Board”) has determined constitutes or would reasonably be expected to lead to a Superior Proposal (as such term is defined in
the Merger Agreement) and that the failure to take such action would be inconsistent with the fiduciary duties of the Company Board under
applicable law.
The Merger Agreement also provides that, in
connection with the termination of the Merger Agreement under certain specified circumstances, including termination by the Company
to accept and enter into an agreement with respect to a Superior Proposal or a Company Adverse Recommendation Change (as defined in the Merger
Agreement), the Company will be required to pay Parent a termination
fee in the amount of $1,573,000.
The Company Board has unanimously (i) determined
that the Merger Agreement and the transactions, including the Offer and the Merger, are fair to and in the best interest of the Company
and its stockholders, (ii) declared it advisable for the Company to enter into the Merger Agreement, (iii) approved the execution
and delivery by the Company of the Merger Agreement, the performance by the Company of its obligations under the Merger Agreement and
the consummation of the transactions, including the Offer and the Merger, (iv) resolved that the Merger shall be effected under Section 251(h) of
the DGCL and (v) resolved to recommend that the stockholders of the Company accept the Offer and tender their shares to Purchaser
pursuant to the Offer.
Tender and Support Agreements
Concurrently with the execution and delivery of
the Merger Agreement, certain stockholders of the Company, including all of the members of the Company Board and certain executive officers
of the Company, who collectively beneficially own approximately 19.58% of the outstanding shares of Company Common Stock entered into Tender
and Support Agreements (the “Support Agreements”) with Parent and Purchaser. The Support Agreements provide, among
other things, that each applicable stockholder will tender all of the shares of Company Common Stock held by such stockholder to Purchaser
in the Offer. The Support Agreements will terminate upon certain events, including upon any valid termination of the Merger Agreement.
The foregoing description of the Merger Agreement
is not complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached as Exhibit 2.1
to this report and incorporated herein by reference.
The Merger Agreement and the foregoing description
thereof have been included to provide investors and stockholders with information regarding the terms of the Merger Agreement. They are
not intended to provide any other factual information about the Company or Parent. The representations, warranties and covenants contained
in the Merger Agreement were made only as of specified dates for the purposes of such agreement, were solely for the benefit of the parties
to such agreement and may be subject to qualifications and limitations agreed upon by such parties. In particular, in reviewing the representations,
warranties and covenants contained in the Merger Agreement and discussed in the foregoing description, it is important to bear in mind
that such representations, warranties and covenants were negotiated with the principal purpose of allocating risk between the parties,
rather than establishing matters as facts. Such representations, warranties and covenants may also be subject to a contractual standard
of materiality different from those generally applicable to stockholders and reports and documents filed with the U.S. Securities and
Exchange Commission (the “SEC”), and are also qualified in important part by a confidential disclosure schedule delivered
by the Company to Parent in connection with the Merger Agreement. Investors and stockholders should not rely on such representations,
warranties and covenants as characterizations of the actual state of facts or circumstances described therein. Information concerning
the subject matter of such representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent
information may or may not be fully reflected in the parties’ public disclosures.
| Item 8.01. |
Other Information. |
On November 16, 2026, the Company issued
a press release announcing the execution of the Merger Agreement. A copy of this press release is filed herewith as Exhibit 99.1.
Additional Information about the Proposed Transaction and Where
to Find It
The tender offer referred to in this report has
not yet commenced. This report is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to
sell shares, nor is it a substitute for the tender offer materials that Parent and its acquisition subsidiary will file with the SEC upon
commencement of the tender offer. At the time the tender offer is commenced, Parent and its acquisition subsidiary will cause to be filed
a tender offer statement on Schedule TO with the SEC, and the Company will file a solicitation/recommendation statement on Schedule 14D-9
with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER
OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED
BY THE COMPANY’S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and
the solicitation/recommendation statement will be mailed to the Company’s stockholders free of charge. A free copy of the tender
offer statement and the solicitation/recommendation statement will also be made available to all stockholders of the Company by accessing
www.rapidmicrobio.com or by contacting the Company’s Investor Relations contact at investors@rapidmicrobio.com. In addition, the
tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at
no charge on the SEC’s website: www.sec.gov, upon filing with the SEC.
THE COMPANY’S STOCKHOLDERS ARE ADVISED TO
READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.
Cautionary Statement Regarding Forward-Looking
Statements
This report contains forward-looking statements
regarding, among other things, the proposed acquisition of the Company by Parent, the expected timetable for completing the transaction,
the Company’s future operating and financial performance, its business strategy and growth outlook, including with respect to its
Growth Direct platform and systems, and its ability to develop and commercialize new and enhanced products and solutions. Words such as
“anticipates,” “continue,” “could,” “may,” “forecasts,” “expects,”
“intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,”
“predict,” “target,” and variations of such words and similar expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees
of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual
results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on
current expectations, estimates and projections about the Company’s industry and business, management's beliefs, and certain assumptions
made by the Company’s management. Actual results could differ materially from those stated or implied in forward-looking statements
due to a number of factors, including but not limited to: (i) risks associated with the timing of the closing of the proposed transaction,
including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of
the proposed transaction will not occur; (ii) uncertainties as to how many of the Company’s
stockholders will tender their shares in the offer; (iii) the possibility that a governmental
entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; (iv) the possibility that competing
offers will be made; (v) the occurrence of any event, change or other circumstance that could give rise to the termination
of the transaction; (vi) the outcome of any legal proceedings that may be instituted against the parties and others related to the
merger agreement; (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business
partners and competitors to the announcement of the proposed transaction, and/or potential difficulties in employee retention as a result
of the announcement and pendency of the proposed transaction; (viii) the Company’s ability to achieve positive cash flow and
otherwise achieve its business objectives; (ix) the Company’s ability to meet its publicly announced guidance and other expectations
regarding its business and operations; (x) the Company’s ability to fulfill customer orders on anticipated timelines or at
all; (xi) the impact of the Company’s existing and any future indebtedness on its ability to operate its business and its ability
to access additional funding under its debt facility; (xii) the effectiveness of the Company’s sales force and sales processes
and its ability to maintain and expand its customer base; (xiii) the Company’s ability to anticipate market needs and successfully
develop and launch new and enhanced products and solutions; (xiv) the Company’s ability to hire and retain qualified employees;
(xv) risks related to the Company’s manufacturing, supply chain, regulatory and intellectual property matters; (xvi) the
impact of inflation, interest rates, tariffs, trade policy and other macroeconomic conditions on the Company’s business and operations;
and (xvii) those risks detailed in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with
the SEC, as well as other documents that may be filed by the Company from time to time with the SEC. The Company cannot assure you that
the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. The forward-looking statements made in this report relate only to events as of
the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statement to reflect events
or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
| |
|
|
|
Exhibit
No. |
|
Description |
| |
|
| 2.1* |
|
Agreement
and Plan of Merger, dated as of November 16, 2026 by and among Merck KGaA, Darmstadt, Germany, EMD Holdings NewCo II, Inc
and Rapid Micro Biosystems, Inc. |
| |
|
| 99.1 |
|
Press
Release issued by Rapid Micro Biosystems, Inc. on November 16, 2026 |
| |
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
| * |
Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedules so furnished. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
RAPID MICRO BIOSYSTEMS, INC. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Sean Wirtjes |
| |
Name: |
Sean Wirtjes |
| |
Title: |
Chief Financial Officer |
Exhibit 99.1
Rapid Micro Biosystems
Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
LEXINGTON, Mass., November 16,
2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology
company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare
products, today announced it has signed a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, has agreed to acquire,
subject to the terms and conditions set forth in the agreement, all outstanding shares of Rapid Micro Biosystems at a price of $0.75 per
share in an all-cash transaction.
"Over the past 18
months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping
customers modernize and automate their quality-control workflows,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
“Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most
of the world's top pharmaceutical manufacturers as customers. We are confident that joining the Life Science business of Merck KGaA, Darmstadt,
Germany will significantly expand the Growth Direct platform’s reach and more fully serve our combined global customer base."
“Quality control
is essential to the reliable manufacture of medicines,” said Paolo Carli, Head of Advanced Solutions for the Life Science business
of Merck KGaA, Darmstadt, Germany. “Our customers need reliable results faster, more efficient quality-control workflows and robust
data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our
existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”
Transaction Details
The transaction is expected
to close in December 2026, subject to the successful completion of the tender offer, including satisfaction of the minimum tender
condition, and other customary closing conditions. Following completion of the transaction, Rapid Micro Biosystems will become part of
the Life Science business of Merck KGaA, Darmstadt, Germany.
Advisors
Perella Weinberg Partners
is serving as financial advisor to the Company and Goodwin Procter LLP is serving as legal counsel.
About Rapid Micro Biosystems
Rapid Micro Biosystems
is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing
and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s
flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows
used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality
control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased
operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure
safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing
in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or
follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor
Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations
under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities
and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Additional Information and Where to Find It
The tender offer described in this communication
has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the
time the tender offer is commenced, Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. (“Purchaser”) will
file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”), and Rapid Micro
Biosystems (“Rapid”) will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND SECURITY
HOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER
OFFER DOCUMENTS) THAT WILL BE FILED BY MERCK KGAA, DARMSTADT, GERMANY AND PURCHASER WITH THE SEC AND THE RELATED SOLICITATION/RECOMMENDATION
STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY RAPID WITH THE SEC, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. These materials (once they become available) will be made available to Rapid shareholders at no cost by the information agent
for the tender offer. Once filed, these documents will be available at no charge on the SEC’s website at www.sec.gov. In addition,
a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may
be obtained free of charge from Merck KGaA, Darmstadt, Germany under the “Investors” section of Merck KGaA, Darmstadt, Germany’s
website at https://www.emdgroup.com/en. A copy of the solicitation/recommendation statement (once it becomes available) also may be obtained
free of charge from Rapid under the “Investor Relations” section of Rapid’s website at https://www.rapidmicrobio.com/.
Forward-Looking Statements
This press release includes “forward-looking
statements” regarding the potential acquisition of Rapid. All statements, other than statements of historical fact, may be forward-looking
statements. These forward-looking statements may be accompanied by such words as “outlook,” “aim,” “anticipate,”
“assume,” “believe,” “contemplate,” “continue,” “could,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“predict,” “potential,” “positioned,” “seek,” “should,” “target,”
“will,” “would” and other words and terms of similar meaning.
Readers are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance
on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and
uncertainties.
Risks and uncertainties include, but are not limited
to: the risk that the closing conditions for the proposed acquisition will not be satisfied, including the risk that the necessary regulatory
approvals may not be obtained or may be obtained subject to conditions that are not anticipated; uncertainty as to the percentage of Rapid
stockholders that will support the proposed acquisition and tender their shares in the offer; the risk of stockholder litigation relating
to the proposed acquisition, including resulting expense or delay; the possibility that the proposed acquisition will not be completed
in the expected timeframe or at all; potential adverse effects to the businesses of Merck KGaA, Darmstadt, Germany or Rapid during the
pendency of the proposed acquisition, such as employee departures or distraction of management from business operations; the potential
that the expected benefits and opportunities of the proposed acquisition, if completed, may not be realized or may take longer to realize
than expected; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement;
potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the
acquisition on the ability to maintain key vendor, supplier or partner relationships; and risks related to the integration of Rapid into
Merck KGaA, Darmstadt, Germany subsequent to the closing of the proposed acquisition and the timing of such integration.
A further list and descriptions of these risks,
uncertainties and other factors can be found in Rapid Micro Biosystems’ Annual Report on Form 10-K for the fiscal year ended
31 December 2025, including in the sections captioned “Forward-Looking Statements” and “Item 1A. Risk Factors,”
and in Rapid Micro Biosystems’ subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Copies of these filings
are available online at www.sec.gov or https://investors.rapidmicrobio.com/. Rapid Micro Biosystems is not under any obligation, and expressly
disclaims any obligation, to update or otherwise revise any forward-looking statements, whether as a result of new information, future
events, or otherwise.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com